An unusual case of aggressive small-cell neuroendocrine carcinoma of cervix in a young woman

2020 ◽  
Vol 4 (2) ◽  
pp. 56
Author(s):  
Vijayan Sharmila ◽  
Padmapriya Balakrishnan ◽  
ThirunavukkarasuArun Babu
Keyword(s):  
Young Woman ◽  
Neuroendocrine Carcinoma ◽  
Unusual Case ◽  
Small Cell ◽  
Small Cell Neuroendocrine Carcinoma ◽  
Carcinoma Of Cervix

An Unusual Case of Primary Small Cell Neuroendocrine Carcinoma of the Breast

2010 ◽  
Vol 16 (6) ◽  
pp. 647-651 ◽  
Author(s):  
Naeem Latif ◽  
Marilin Rosa ◽  
Laila Samian ◽  
Fauzia Rana
Keyword(s):  
Neuroendocrine Carcinoma ◽  
Unusual Case ◽  
Small Cell ◽  
Carcinoma Of The Breast ◽  
Small Cell Neuroendocrine Carcinoma

scholarly journals Mixed large and small cell neuroendocrine carcinoma and endometrioid carcinoma of the endometrium with high microsatellite instability: A case report and literature review

2021 ◽  
Vol 9 ◽  
pp. 2050313X2199920
Author(s):  
Kotaro Inoue ◽  
Kentaro Kai ◽  
Shimpei Sato ◽  
Haruto Nishida ◽  
Koji Hirakawa ◽  
...  
Keyword(s):  
Microsatellite Instability ◽  
Neuroendocrine Carcinoma ◽  
Immune Checkpoint Blockade ◽  
Japanese Woman ◽  
Endometrial Biopsy ◽  
Small Cell ◽  
Endometrioid Carcinoma ◽  
Small Cell Neuroendocrine Carcinoma ◽  
Mutation Burden ◽  
Solid Part

A 65-year-old, gravida 3, para 2 Japanese woman was referred to our hospital for symptomatic thickening of the endometrial lining. Endocervical and endometrial cytology revealed an adenocarcinoma. The endometrial biopsy specimen was mixed, with a glandular part diagnosed as endometrioid carcinoma and a solid part diagnosed as high-grade mixed large and small cell neuroendocrine carcinoma (L/SCNEC). She underwent extra-fascial hysterectomy with bilateral salpingo-oophorectomy, complete pelvic and para-aortic lymphadenectomy, and omentectomy (FIGO IIIB, pT3b pN0 M0). She currently has no deleterious germline mutation, but high tumor mutation burden and high microsatellite instability (MSI) were identified. She underwent six cycles of platinum-based frontline chemotherapy and achieved complete remission. Immune checkpoint blockade therapy is a promising second-line therapy for MSI-high solid tumors. However, the MSI or mismatch repair (MMR) status of endometrial L/SCNEC remains unclear in the literature. Universal screening for MSI/MMR status is needed, particularly for a rare and aggressive disease.

Sign in / Sign up

Export Citation Format

Share Document